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Safety and effectiveness of propranolol in
severely burned patients: systematic review
and meta-analysis
Ramiro Manzano-Nunez1,2, Herney Andrés García-Perdomo2, Paula Ferrada3, Carlos Alberto Ordoñez Delgado4,
Diego Andrés Gomez2 and Jorge Esteban Foianini5*
Abstract
Background: The objective of this systematic review was to determine the effectiveness and safety of propranolol
compared to placebo or usual care for improving clinical relevant outcomes in severely burned patients (TBSA >20%).
Methods: Relevant articles from randomized controlled trials were identified by a literature search in MEDLINE,
EMBASE, and CENTRAL. We included trials involving patients with a severe burn (>20% of total body surface
area affected). Trials were eligible if they evaluated propranolol and compared to usual care or placebo. Two
investigators independently assessed articles for inclusion and exclusion criteria and selected studies for the
final analysis. We conducted a meta-analysis using a random-effects model.
Results: We included ten studies in our systematic review. These studies randomized a total of 1236 participants.
There were no significant differences between propranolol and placebo with respect to mortality (RD −0.02 [95% CI −0.
06 to 0.02]), sepsis (RD −0.03 [95% CI −0.09 to 0.04]), and the overall hospital stay (MD −0.37 [−4.52 to 3.78]).
Propranolol-treated adults had a decrease in requirements of blood transfusions (MD −185.64 [95% CI −331.06
to −40.43]) and a decreased heart rate (MD −26.85 [95% CI −39.95 to −13.75]).
Conclusions: Our analysis indicates that there were no differences in mortality or sepsis in severely burned
patients treated with propranolol compared with those who had usual care or placebo. However, the use of
propranolol in these patients resulted in lower requirements of blood transfusion and lower values of heart
rate. The evidence synthesized in this systematic review is limited to conclude that propranolol reduces the
length of hospital stay among severely burned patients. Future trials should assess the impact of propranolol
on clinically relevant outcomes such as mortality and adverse events.
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Background
Burn injuries are among the most severe of all injuries
[1] with approximately 90% of cases occurring in low-
and middle-income countries [2]. Burns are a common
cause of morbidity and mortality, and most occur in a
domestic setting with children from birth through 4 years
having the highest burden of the condition. Episodes
occur commonly at home and principally due to scalds,
hot objects, and fires [3, 4]. For adults, the incidence of
burns is low until the 30s, with cases occurring at home,
outdoors, and at workplaces in equal proportions [1].
The incidence of burns in low- and middle-income
countries is 1.3 per 100,000 population whereas in high-
income countries is approximately of 0.14 per 100,000
population with burn injuries ranking the top 15 leading
causes of burden of disease globally [2, 5].
Burn injuries covering more than 20% of the total
body surface area (TBSA) cause an inflammatory and
subsequent hypermetabolic response that starts immedi-
ately post-burn and can persist for years [6, 7]. Hyper-
metabolic state has two aspects—the “ebb” and “flow”
phases. The ebb phase, occurring within the first 48 h
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after injury, is associated with decreased cardiac output,
oxygen consumption, and metabolic rate. The chronic
“flow” phase is a critical phase that requires medical
intervention to reduce the risk of fatal outcomes [8].
The release of cytokines and other pro-inflammatory
mediators at the site of injury has a systemic effect once
the burn reaches 20% of total body surface area. Injuries
greater than this percentage invariably results in severe
impairments of cardiovascular, respiratory, metabolic,
and immunological functions derived from hypermeta-
bolic changes [9]. The hypermetabolic response along
with catecholamines and corticosteroids increase liver
and cardiac work, impair muscle function, increase the
risk of sepsis, and produce hormonal abnormalities that
augment morbidity and mortality [6, 9–11].
Several interventions have been proposed to decrease
the hypermetabolic response and to improve outcomes
in the burned patient [12–16]. Propranolol through
β-adrenergic receptor blockade has been proposed as an
effective strategy for reducing post-burn catabolism and
therefore to improve outcomes in burned patients. The
objective of this systematic review was to determine the
effectiveness and safety of propranolol compared to pla-
cebo or usual care for improving clinical relevant
outcomes in severely burned patients (TBSA >20%).
Methods
This systematic review and meta-analysis was conducted
according to the recommendations of the Cochrane Col-
laboration and following the PRISMA Statement. The
PROSPERO registration number is CRD42016042230.
Inclusion criteria
We included only randomized controlled trials (RCTs)
involving patients with a severe burn, defined as a burn
with an affected area greater than 20% of the total body
surface area (TBSA). Trials were eligible if they evalu-
ated propranolol as the intervention of interest in adults
or children and compared to usual care or placebo. We
excluded trials where propranolol was compared to
other pharmacologic interventions and trials evaluating
the combination of propranolol with other interventions.
Two investigators independently assessed articles for
inclusion and exclusion criteria and selected studies
for the final analysis, with divergences finally resolved
by consensus.
Outcomes
We prespecified clinical relevant outcomes as our primary
outcomes. Those included mortality, adverse events, need
for transfusions/blood loss, the occurrence of infections/
sepsis, and length of hospital stay. Secondary outcomes
were heart rate, hypertriglyceridemia, and hyperglycemia.
Only those trials providing sufficient information (i.e.,
measures of treatment effects and the associated preci-
sion) were included in our statistical analysis.
Search methods
Literature search strategy was built according to current
recommendations (Additional file 1: Table S1) [17–19].
We searched MEDLINE, EMBASE, and CENTRAL from
inception to 2016. We also hand-searched references
from relevant narrative reviews and previous systematic
reviews for more trials. Other sources were thesis data-
bases, OpenGrey and Google Scholar. Authors were
contacted to complement data by e-mail. No language
restrictions were used.
Study selection and data collection
Two individuals independently assessed the titles and
abstracts identified by the searches for potential eligi-
bility, and the full-text articles were retrieved for
those that appeared relevant. Two investigators inde-
pendently assessed full-text articles for final eligibility.
Disagreements were resolved by consensus or by a
third, independent reviewer. The following informa-
tion was independently extracted using a standardized
form: study design, geographic location, authors
names, title, objectives, inclusion and exclusion criteria,
the number of patients included, losses to follow-up, the
definition of interventions, definitions of outcomes, out-
comes measures, funding, and status of data on clinical
trials website.
Risk of bias
The internal validity of each trial included in this review
was critically evaluated for bias according to the
Cochrane Collaboration tool for assessing the risk of
bias [20] which covers sequence generation, allocation
concealment, blinding, incomplete data, selective report-
ing, and other biases. Two independent investigators
made a judgment about the possible risk of bias from
extracted information, rated as “high risk,” “low risk,” or
“unclear risk”. We computed a graphic representation of
potential bias using RevMan 5.3.
Data analysis/synthesis of results
A meta-analysis was performed to assess the overall out-
comes of propranolol compared to usual care or
placebo. The statistical analysis was performed using
Review Manager 5.3 (RevMan® 5.3). For dichotomous
outcomes, we extracted data on the total number of par-
ticipants, the number that experienced the outcomes,
and the number analyzed. For continuous outcomes, we
extracted end-value means with standard deviations
(SD). Whenever possible, we used results from an
intention-to-treat population.
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Mean differences (MD) and risk differences were
pooled using a random-effects model. The results were
reported in forest plots of the estimated effects of the in-
cluded studies with a 95% confidence interval (95% CI).
Meta-analysis was considered since the included studies
were similar in terms of participants, interventions, and
outcomes (clinical homogeneity). Heterogeneity was
evaluated using the I2 test. For the interpretation, it was
determined that the values of 25, 50, and 75% in the I2
test corresponded to low, medium, and high levels of
heterogeneity, respectively.
Results
We identified 164 records from our searches, of which
19 trials were eligible to be included in our systematic
review. After applying inclusion and exclusion criteria,
ten studies [21–30] were included in the systematic re-
view, all of them in the qualitative synthesis and eight in
quantitative synthesis (meta-analysis). Figure 1 shows
the flowchart for the selection of randomized trials.
Characteristics of included studies
Included trials were published between 2001 and 2015.
These trials randomized a total of 1236 participants with
a sample size ranging from 25 to 406 (median, 76; inter-
quartile range, 58.5–195.5). Five trials (50%) [22–25, 27]
were single-center trials. Of the ten RCTs included, nine
recruited participants from the USA and one trial re-
cruited patients from Iran [27]. Losses to follow-up were
reported in four trials [22–24, 29], and finally, an
intention-to-treat analysis was performed in two trials
[22, 24]. Main characteristics from included studies were
summarized in Additional file 2: Appendix 1.
Six RCTs were done in adults and four were done in
children [23–25, 29]. Regarding how the condition was
defined, four RCTs [23, 25, 26, 28] included patients
with burns greater than 40% of TBSA, five [21, 22, 24,
29, 30] included patients with burns greater than 30% of
TBSA, and one trial [27] included patients with burns
between 20 and 50% of TBSA. Interventions and com-
parators were very similar, with propranolol (at similar
doses) and placebo or usual care being the intervention
and comparator, respectively, in all trials. The similarity
in interventions and comparators between trials could
result in low clinical diversity at this point. Main charac-
teristics of participants from individual RCTs are
summarized in Table 1.
With respect to outcomes (see Additional file 1:
Table S1), four trials [22, 24, 25, 27] presented mor-
tality data, in three trials [21, 22, 27], the quantity of blood
transfused was reported, three trials [23, 25, 27] measured
occurrence of sepsis, five trials [22, 24, 25, 27, 29] reported
length of hospital, eight trials [21–24, 26, 28–30] defined
hemodynamic parameters such as heart rate, mean arterial
pressure, cardiac output, and/or stroke volume as part of
the outcomes measured. Three trials [21, 22, 27]
presented data about wound healing in terms of the num-
ber of grafting procedures and the average time between
grafting procedures, and only one trial [22] presented data
about adverse effects of propranolol.
Risk of bias
Seven (70%) and ten trials (100%) were rated as unclear risk
of bias for random sequence generation and allocation
Fig. 1 Flowchart according to PRISMA guidelines
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concealment, respectively; the remaining three trials (30%)
from the random sequence generation domain were rated
at low risk of bias. Only one trial (10%) reported masking
of study participants, and the remaining nine trials (90%)
were rated at unclear risk of bias for this domain. All trials
were rated at unclear risk of bias in terms of blinding of
outcome assessors. Three trials (30%) were rated as high
risk of attrition bias because of losses to follow-up. High
risk of selective reporting was found in eight trials (80%);
thus, a dangerous quantity of reporting bias could have
been introduced from those trials but it was difficult to esti-
mate the likely magnitude and the likely direction of this
bias. High risk of other biases was found in six trials (60%)
due to small sample sizes. Five trials (50%) reported receiv-
ing funding for the research, and none was funded by
pharmaceutical industry. Finally, none of the trials posted
results in clinical trials website (https://clinicaltrials.gov/)
and six trials reported receiving ethical approval. The over-
all risk of bias of the included RCTs is best represented in
Figs. 2 and 3.
Outcomes
There were no significant differences between propran-
olol and placebo/usual care with respect to mortality
(RD −0.02 [95% CI −0.06 to 0.02]), and also, no differ-
ences were found in the sub-group analysis when asses-
sing this outcome in children (RD −0.02 [95% CI −0.06 to
0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07])
(Fig. 4). Similarly, no significant differences were found
when assessing overall occurrence of sepsis (RD −0.03
[95% CI −0.09 to 0.04]) with no differences in children
(RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04
[95% CI −0.24 to 0.15]) (Fig. 5). When assessing the length
of hospital stay, propranolol did not shorten the overall
number of days of hospitalization when compared to
usual care or placebo (MD −0.37 [−4.52 to 3.78]) but this
was not sustained when assessing sub-groups. In the sub-
group analysis, the use of propranolol was associated with
a lower length of hospital stay in adults (MD −6.59 [95%
CI −10.18 to −3.0]), a fact that did not occur in children
(MD 2.30 [95% CI −3.36 to 7.96]).
With respect to blood transfused, propranolol was
associated with a lower amount of transfused blood
(measured in milliliters) in adults (MD −185.64 [95%
CI −331.06 to −40.43]). Propranolol was associated
with lower values of heart rate (beats per minute)
when compared to usual care (MD −26.85 [95% CI
−39.95 to −13.75]) and this was consistent in adults
Table 1 Characteristics of participants. Age is described as mean and standard deviation
No. Study Group Total number
of randomized
patients
Age TBSA (%) of
patients to be
included
Country Socio-demographics
1 Williams 2011 [29] Propranolol 125 7 (5) Burns >30% USA Not described
Standard care 215 8 (5)
2 W Norbury 2007 [28] Propranolol 33 Not described Burns >40% USA Not described
Standard care 33 Not described
3 Wurzer 2015 [30] Propranolol 43 Not described Burns >30% USA Not described
Standard care 39
4 Ali 2014 [21] Propranolol 21 Not described Burns >30% USA Not described
Standard care 21
5 Komak 2012 [26] Propranolol 29 Not described Burns >40% USA Not described
Standard care 35
6 Ali 2015 [22] Propranolol 35 41 (14) Burns >30% USA Not described
Standard care 34 38 (16)
7 Herndon 2012 [24] Propranolol 90 7 (5) Burns >30% USA Majority of participants were
Hispanic: 97% in the control
group and 91% in the
propranolol group
Standard care 89 7 (5)
8 Akbar Mohammadi 2009 [27] Propranolol 37 27.21 (9.73) Burns 20–50% Iran Not described
Standard care 42 24.54 (12.06)
9 Jeschke 2007 [25] Propranolol 102 7.2 (0.6) Burns >40% USA Not described
Standard care 143 7.8 (0.4)
10 Herndon 2001 [23] Propranolol 12 6.6 (1.5) Burns >40% USA Not described
Standard care 12 7.8 (1.4)
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(MD −32.54 [95% CI −38.45 to −26.63]) and children
(MD −19.0 [95% CI −31.12 to −6.88]).
Finally, it is important to mention that studies done in
children did not report data about transfused blood. On
the other hand, some of our primary outcomes are not
reported and this is because primary research did not re-
port data on hypertriglyceridemia and hyperglycemia.
Sensitivity analysis
Of the ten studies included in our systematic review, eight
were rated as high risk for selective reporting; therefore,
we decided to exclude those studies from our quantitative
synthesis to evaluate the effect of this bias on results. We
found that there were no differences in mortality (RD
−0.12 [95% CI −0.32 to 0.07]) and quantity of blood trans-
fused (MD −405 [95% CI −1343.48 to 533.48]) when com-
paring propranolol and usual care after excluding studies
with high risk of selective reporting.
On the other hand, three of the ten studies were rated
as high risk for attrition bias; thus, after excluding those
studies from quantitative results, we found that propran-
olol was associated with a lower length of hospital stay
in children (MD −2.0 [CI 95% −2.51 to −1.49]) and
adults (MD −6.54 [95% CI −10.19 to −2.89]).
Discussion
The present study was designed to determine the effect-
iveness and safety of propranolol, compared to placebo
or usual care, for improving clinical relevant outcomes
in severely burned patients. In summary, no significant
differences were found between propranolol and usual
care in terms of mortality and sepsis occurrence.
Propranolol-treated adults had a decrease in require-
ments of blood transfusion and a decreased heart rate.
There was no difference in the overall length of hospital
stay. However, the subgroup analysis showed decreased
hospital stay in adults treated with propranolol. Further-
more, the sensitivity analysis revealed significantly
decreased hospital stay in both adults and children
treated with propranolol.
Severe burn injuries cause a hypermetabolic re-
sponse driven by supraphysiologic elevations in stress
hormones, catecholamines, and inflammatory media-
tors [6, 9, 11]. The hypermetabolic response is char-
acterized by increased peripheral lipolysis, increased
muscle wasting, elevated resting energy expenditure,
and suppressed immune function. This response im-
pedes recovery or leads to organ failure and death
[9]. Therefore, the hypermetabolic response can be
seen as an intermediate variable in the causal pathway
between burns and relevant outcomes in burned
patients; and thus, it is not irrational to think that
the use of propranolol, by mitigating the deleterious
effects of the hypermetabolic response, can result in
improved outcomes among severely burned patients.
Burns impose a significant challenge and are associ-
ated with mortality rates between 1.4 and 18% with age
groups and greater percentage total body surface area
(TBSA) affected being associated with greater fatality
rates [31–33]. It is estimated that 265,000 deaths every
year are caused by burns, with the higher proportion of
these fatalities occurring in low- and middle-income
Fig. 2 Risk of bias from individual study
Fig. 3 Risk of bias across studies
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countries [2, 34], places where burns are a leading cause
of mortality and a public health problem; thus, interven-
tions to reduce mortality in burned patients could be of
great value. Our study found that the use of propranolol
did not significantly reduce mortality in patients with
severe burns, a result that is consistent with previous
research [24].
Burns are associated with changes in the immune re-
sponse. Severe burns induce a state of immunosuppres-
sion [35] that predisposes burn patients to infectious
complications and sepsis [36]. In theory, the use of
β-adrenergic blocking agents could improve immune
status through the suppression of catecholamine-
mediated hypermetabolism in critically ill patients.
However, the potential immunological side effects of
the β-adrenergic blockade are not well elucidated. Fur-
thermore, research in animal models has found that the
use of pharmacologic β-adrenergic blockade during
sepsis is associated with disturbances in the immune
system that predisposes to organ dysfunction and asso-
ciated mortality [37, 38]. The current study found no
significant differences between propranolol and
placebo/usual care when measuring sepsis occurrence.
Overall, the use of propranolol in severely burned
patients was not associated with a lower length of hos-
pital stay. However, after performing subgroup and sen-
sitivity analyses, the use of propranolol was associated
with a lower length of hospital stay (LOS) in severely
burned adults and children. This finding could be of
great importance if we take into account that burn
patient management requires significant financial re-
sources, and LOS has a large impact on cost. It is not
clear how propranolol could reduce the length of stay
since many factors are related to this outcome. Such
Fig. 4 Forrest plot for mortality (propranolol vs usual care)
Fig. 5 Forrest plot for sepsis (propranolol vs usual care)
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factors include the area and deepness of the burn, the
sex and age of the patient, and the time until the initi-
ation of the treatment [39, 40]. Although reductions of
time spent in the hospital will reduce costs, and there-
fore are of great importance for managerial attention
[41], our results provide limited evidence to conclude
that propranolol decreases the length of hospital stay.
The sustained elevation of catecholamines after severe
burn injuries may be detrimental to the myocardium.
Severe burns may cause cardiac deficiency, myocardial
hypoxia, and cardiac death [42]. In this setting, propran-
olol has been proposed as an intervention aimed to im-
prove the hemodynamic state of severely burned patients.
Our pooled analysis showed, as expected, that propranolol
reduced heart rate in severely burned patients. This result
seems to be consistent with other research which found
that the administration of propranolol improves cardiac
physiology and reduces cardiac stress among patients with
severe burns [43, 44]. For example, Brown et al. [44] re-
ported a 22% decrease in resting heart rate after 2 weeks
of propranolol treatment in burned adults. Herndon et al.
showed a 20% decrease in baseline heart rate with the use
of propranolol in burned children [23]. Although the use
of propranolol in severely burned patients can improve
cardiac physiology, it is also associated with frequent
episodes of hypotension and bradycardia [44].
Another important finding was that propranolol-
treated adults had a decrease in requirements of blood
transfusion. A possible explanation for this result might
be that the use of propranolol in severe burns improves
wound healing and therefore decreases the number of
skin graft procedures [27]. In major burns, the blood
loss from one debridement and grafting can be enor-
mous. Such losses can result in cardiovascular derange-
ments and even shock. Therefore, decreasing the
number of skin graft procedures reduce the chance for
major bleeding. Even if propranolol can decrease re-
quirements of blood transfusion, it is important to keep
in mind that several factors influence the decision to
transfuse a burn patient and also several factors are
associated with transfusions thresholds. A previous study
explored the relationship between patient characteristics
and number of transfusions. This study found that the
number of PRBC and plasma transfusions was signifi-
cantly influenced by TBSA burn, the presence of co-ex-
isting inhalation injury, and the type of anticoagulation
used [45]. Palmieri and Greenhalgh [46] used a survey to
identify burn center physician blood transfusions prac-
tices. They found that inhalation injury influenced the
decision to transfuse blood and that the most frequent
reasons for transfusions were hemorrhage, anemia, hyp-
oxia, and cardiac disease.
A key component of evidence-based medicine is the
knowledge about the balance of benefit to harm.
Therefore, we must acknowledge that only one [22] of
the trials reported adverse events of propranolol and
that was one of the reasons why we rated eight trials as
having a high risk for selective reporting. Adverse events
reported in the trial by Ali et al. [22] included bradycar-
dia, bradypnea, hypotension, and ischemia. Brown et al.
[44] studied the safety of propranolol use in adult pa-
tients with burn injuries. In this study, the use of pro-
pranolol was associated with frequent episodes of
hypotension and bradycardia. The authors concluded
that despite the potential beneficial effects, burn care
providers must recognize the potential iatrogenic
hemodynamic effects of propranolol. Previous research
on other conditions in children and adults have found
that propranolol is associated with potentially life-
threatening reactions such as pulmonary edema, shock,
or complete heart block [47–49].
The most important limitation of this systematic re-
view lies in the fact that only one study utilized mortality
as a primary outcome [27]. From an orthodox view,
evaluation of mortality in this study is preliminary as the
remaining studies reporting mortality data are under-
powered for this outcome. However, systematic reviews
should include all outcomes that are likely to be mean-
ingful to stakeholders even if those are not reported as
primary endpoints in the primary research [20].
To develop a full picture of the effectiveness of
propranolol on burns, additional studies will be needed
that include clinical relevant outcomes, such as mortality
as their primary outcomes. On the other hand, as only
one trial reported data on adverse effects of propranolol,
a further study with more focus on the safety of
propranolol is therefore suggested.
Conclusions
Propranolol has been used as a therapy to reduce the
deleterious effects of hypermetabolic response. Our ana-
lysis indicates that although lower in propranolol-treated
patients, mortality and sepsis were not significantly dif-
ferent between compared groups. However, the use of
propranolol in severely burned patients resulted in lower
requirements of blood transfusion and lower values of
heart rate. On the other hand, the evidence synthesized
in this systematic review is limited to conclude that pro-
pranolol reduces the length of hospital stay among se-
verely burned patients. Future trials should assess the
impact of propranolol on clinically relevant outcomes
such as mortality and adverse events.
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